

17.03.2017

---

### Corporate News of MPH Mittelständische Pharma Holding AG

**2016: Temporary IFRS results, annual net profit of €81.45m, €1.90 profit per share (previous year: €84.10m, €1.96 profit per share). Equity €215.33m (previous year: €139.02m).**

MPH Mittelständische Pharma Holding AG, Berlin (ISIN: DE000A0L1H32), announces the temporary IFRS group results for fiscal year 2016. In fiscal year 2016, the temporary IFRS annual net profit was €81.45m (€1.90 profit per share).

HAEMATO AG, M1 Kliniken AG, and CR Capital Real Estate AG holding companies listed in the Frankfurt Stock Exchange operated successfully in 2016.

In fiscal year 2016, HAEMATO achieved an increase in turnover of 20%, an EBIT growth of 63%, and an increase of the annual net profit of 94%.

During the fiscal year, the HAEMATO share price increased from €4.94 to €6.44. As in the previous year, the dividend paid in June 2016 was €0.30 per share.

M1 Kliniken AG expanded its clinic in Berlin to 6 operating theatres and 35 patient beds. After some more openings, 13 M1 centres of competence are now ready to serve our customers throughout Germany. The financial data for 2016 will be published on 31.03.2017.

The M1 share price has almost doubled from €5.34 to €10.55 during the fiscal year. The dividend paid in June 2016 was €0.30 per share.

CR Capital Real Estate AG reported progress in the project developments at the annual general meeting on 18.08.2016. The 2016 financial data will presumably be published in March 2017.

Following last year's annual net profit of €84.10m, the annual net profit of €81.45m is another record result. This allows us to be confident regarding the further development in 2017. In each year since 2005, the health care industry has expanded its gross value added more strongly than the overall economy. MPH systematically benefits from the growth of HAEMATO AG in the field of pharmaceuticals in the insurance-financed market and through the growth of M1 Kliniken AG in the direct-payer market, the so-called secondary health care market.

#### Contact:

MPH Mittelständische Pharma Holding AG  
Martin Gorczinski  
Grünauer Straße 5  
D-12557 Berlin

Phone: +49 (0) 30 897 30 8660  
Fax: +49 (0) 30 897 30 86 69

E-mail: [ir@mph-ag.de](mailto:ir@mph-ag.de)  
Web: [www.mph-ag.de](http://www.mph-ag.de)

17.03.2017

---

The results situation allows us to propose at the annual general meeting a dividend of €0.12 per share, which is the same amount as last year", note both Patrick Brenske and Dr Christian Pahl, Members of the Board of MPH.

### **About MPH Mittelständische Pharma Holding AG:**

MPH AG is an investment company strategically focusing on buying, growing and selling companies and company shares in particular from growth segments of the health care market. This includes both insurance and privately funded segments. However, MPH also makes use of potentials from high-growth industries outside of the health care market.

MPH Mittelständische Pharma Holding AG is listed in the Basic Board (Open Market) of the Frankfurt Stock Exchange.

Key figures for the share of MPH Mittelständische Pharma Holding AG:

Subscribed capital: €42,813,842

Listed class of share: Bearer shares

ISIN: DE000A0L1H32

WKN: A0L1H3

Ticker symbol: 93M

**Contact:** Mr Martin Gorczinski  
MPH Mittelständische Pharma Holding AG  
Grünauer Straße 5  
D-12557 Berlin

Phone: +49 (0) 30 897308660 Fax: +49 (0) 30 897308669  
E-mail: [ir@mph-ag.de](mailto:ir@mph-ag.de) Web: [www.mph-ag.de](http://www.mph-ag.de)

### **Contact:**

MPH Mittelständische Pharma Holding AG  
Martin Gorczinski  
Grünauer Straße 5  
D-12557 Berlin

Phone: +49 (0) 30 897 30 8660  
Fax: +49 (0) 30 897 30 86 69

E-mail: [ir@mph-ag.de](mailto:ir@mph-ag.de)  
Web: [www.mph-ag.de](http://www.mph-ag.de)